Medicine is just the beginning

    • Keynotes
    • Keynotes
The new battlegrounds are not where you expect
  • Why manufacturing and supply chain will be the key differentiator as direct-to-patient supply and admin are the success factors for personalised, biological and specialised medicines
  • Prevention is better than cure: why prophylactic treatments, gene and cell therapies and genomics are priority areas for investment today
    • Keynotes
The Authenticity Factor: how CMOs can pioneer rapid-reaction strategy based on continuous data input
  • Hear the argument for re-centralisation of medical teams in order to create a core of medical expertise
  • Determine to what degree medical and commercial must align – and how to empower them with high-grade datasets
    • Keynotes
Let the health entrepreneurs show you how
  • Witness elevator pitches from 6 hand-selected healthcare startups who promise to disrupt pharma – and who could be your next partner
  • Understand the true risk, ambition and what is possible with minimal resources
    • Keynotes
Your agility ability: why adopting more iterative and experimental innovation techniques need a new type of learning culture
  • Why your revenue-focussed objectives will fail in an entrepreneurial environment
  • Ways you can create faster, more experimental innovation without sacrificing safety and reliability
    • Keynotes
Exceed the expectations of increasing consumerization
  • Where we need to move from B2B to B2C and what the finest in FMCG and Financial Services are doing to remodel
  • Move patients from ‘empowered’ to ‘being in charge’ by investing in literacy and enabling them as adjudicators within the access equation.
    • Keynotes
How can we create joint-venture patient initiatives and prevent patient confusion?
  • Why it makes long-term commercial sense to avoid the short-term land grab for your own app or PSP
  • See how new projects have aligned the drivers and incentives between difference companies to enable true partnership to occur
    • Keynotes
We fight for the patient – and the patient fights for us
  • How the smartest companies are able to go beyond empowerment, beyond advocacy and work with patients for sustained access in a virtuous circle
  • Why your goal must be to have the most comprehensive patient insights if you are ever going to gain trusted partner status
    • Keynotes
Prevention is better than cure: how the future of pharma depends on today’s investment in regenerative medicine, cell therapies and genomics
  • How the biological mechanisms can be enhanced and repaired through cost-effective methods for the harvesting, expansion, manipulation and purification of the body’s cells.
    • Keynotes
Speakers

Brent Saunders, CEO, Allergan

Kris Sterkens, Company Groups Chairman, Europe, Middle East and Africa, Janssen

David Meek, CEO, Ipsen

Belén Garijo, Member of the Executive Board, CEO Healthcare, Merck Group

Zach Weinberg, Co-Founder, Flatiron Health

Gitte Aabo, President & CEO, LEO Pharma

Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca

Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

Bharat Tewarie, EVP & Chief Marketing Officer, UCB

Ryan Olohan, Managing Director, Healthcare, Google

Marc Princen, Executive Vice Presidnet and President, International Business, Allergan

Colin Sims, Senior Vice President, Head, Transversal Corporate Strategy, Sanofi

Kabir Nath, President and CEO, Otsuka North America

Andrew Thompson, Co-Founder and CEO, Proteus Digital Health

Catalyse trust in RWE

    • Data & RWE
    • Market Access
    • Data & RWE
    • Market Access
Stakeholder Panel: Understand the acceptability of RWE across global regulatory decision-making
  • Explore the evolving role of RWE in the evidence lifecycle, quality expectations and the possibility of regulatory grade RWE
  • Discuss the impact of regulatory policies, such as 21st Century Cures Act, on the global adoption of RWD into R&D and Access framework

Khair ElZarrad, Deptuy Director, Office of Medical Policy, FDA

Giuseppe Rosano, Member CVWP, European Medicines Agency, Consultant Cardiologist, Agenzia Italiana del Farmaco, EMA

Christoph von der Goltz, Senior Director, Head of HEOR & RWE, Lundbeck

    • Data & RWE
    • Market Access
Drive the adoption of RWE
  • Explore key driving forces preventing increased adoption of RWE from a force field perspective
  • Discuss approaches to further build a robust European healthcare data-scape

David Leather, Medical Vice President, Respiratory Franchise, GSK

    • Data & RWE
Federated & harmonised real world research in Europe – 2020 and beyond
  • Discuss key challenges and objectives from key European projects (EMIF & EHDEN) in creating a sustainable harmonised EU data ecosystem
  • Explore current and predicted impact IMI European Health Data Network (EHDEN) now underway

Nigel Hughes, Scientific Director, Janssen

Create your data symphony

    • Medical Affairs
    • Data & RWE
    • Market Access
    • Medical Affairs
    • Data & RWE
    • Market Access
Advance data generation by unlocking the value of academic collaboration
  • Ensure full transparency and compliance to maintain ethics and enhance pharma’s external image
  • Understand the full potential of using academic partners in comparison to traditional CROs

Thomas D'Hooghe, Vice President and Head, Global Medical Affairs Fertility, Merck Group

    • Medical Affairs
    • Data & RWE
    • Market Access
Hone your RWE generation strategy in Specialty and Rare Diseases
  • Use RWE to define clinical trial endpoints and meet Market Access goals in rare diseases
  • Understand the multiple channels and high quality data sources available and usable

Dirk Vander Mijnsbrugge, VP, Medical Affairs Lead International Developed Markets , Pfizer

    • Medical Affairs
    • Data & RWE
Machine learning and emerging analytical approaches for Regulatory and Safety RWE
  • Lessons learnt in building internal capacity to accept new technology through training and partnerships
  • How to take advantage of new capabilities to combine, use and extract data while staying compliant and ensuring appropriate impact"

Andrew Bate, Senior Director, Analytics Team Lead, Epidemiology, Pfizer

Reimagine R&D with RWE

    • Medical Affairs
    • Data & RWE
    • Medical Affairs
    • Data & RWE
Modernise the development paradigm with RWE
  • Explore how Boehringer are using RWE to complement data from clinical trials with new levels of patient population understanding
  • Enhance development efforts with easily accessible and communicable RWD platforms

Amanda Golembesky, Head of Real World Evidence Analytics Center of Excellence, Boehringer Ingelheim

    • Medical Affairs
    • Data & RWE
Panel: Understand how to prove real-world effectiveness pre-launch
  • Case Study: Explore how phase II of the IMI GetReal programme is developing industry-wide standards and methodologies to accelerate adoption of RWE
  • Discuss how to incorporate RWE into the traditional R&D framework and tools available now to enhance operational efforts

Páll Jónsson, Associate Director Science Policy and Research, NICE

Rob Thwaites, Former Senior Director, Strategy, Global Outcomes Research (GOR) and Head, GI, GOR, Takeda

Wim Goettsch, Special Advisor HTA, ZINL; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht, ZINL

RWE driven Market Access

    • Patients
    • Data & RWE
    • Market Access
    • Data & RWE
    • Market Access
Understand how RWE assessment fits into different HTA assessment methodologies across Europe
  • Bring it home: use local affiliates to feed into international RWE and access planning
  • Compare and contrast the range of HTA evidence hierarchies across Europe

Wim Goettsch, Special Advisor HTA, ZINL; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht, ZINL

    • Patients
    • Data & RWE
    • Market Access
Smarter use of PROs to turn patient value into payer value
  • How to move beyond clinical measures and successfully capture what truly matters to patients to secure access

Daniel Jackson, Global Head, Market Access Solutions and Strategy, UCB

    • Data & RWE
    • Market Access
Value-based contracting: use best-in-class predictive analytics
  • Forecast commercial performance by establishing value benchmarks and data quality from the outset

Real-World Evidence Focused Roundtables

    • Data & RWE
    • Data & RWE
  • Design your internal RWE function: capability requirements, future proofing, ownership, investment needed
  • The impact of GDPR: discuss the impact existing and future privacy regulations/policies may
  • Meet RWE regulatory standards: which internal functions should take leadership/ensure relative quality in emerging area
  • Tapping Academic collaboration: explore the full potential of academic partnership for data generation
  • Changing the public perception: pharma’s role in educating and improving negative public attitudes to health data use
  • RWE in clinical trials: how best to bring big data into the development process
  • The pragmatic solution: why defining the right question for pragmatic studies is key
  • The future of data standardisation: explore existing and future European efforts to create a sustainable harmonised EU data ecosystem

Nigel Hughes, Scientific Director, Janssen

Thomas D'Hooghe, Vice President and Head, Global Medical Affairs Fertility, Merck Group

Market Access stakeholder harmony

    • Market Access
    • Medical Affairs
    • Market Access
    • Medical Affairs
Panel: How to work more openly with HTAs to improve patient care and match medical innovation
  • Discuss the changing needs for value assessment as levels of effectiveness increase
  • How to foster more transparent partnership with government bodies

Martin Price, Vice President, Health Economics, Market Access & Reimbursement, Janssen

Adam Kundzewicz, Global Head of Strategic Market Access Initiatives, Boehringer Ingelheim

    • Market Access
Panel: Drive market access innovation in a risk averse environment
  • Explore the next steps in creating an environment capable of successfully enacting more outcomes-based agreements
  • Strengthen stakeholder alignment with understanding of the groundwork capabilities needed for data needs

Ulf Staginnus, Senior Vice President, Head Global Market Access & Pricing, Ipsen

Drive Access innovation

    • Market Access
    • Patients
    • Market Access
Pricing innovation in the face of CAR-T and gene therapy
  • Explore how to implement appropriate outcomes-based pricing models to match treatment innovation
  • Understand the new needs of payers given the increasing levels of complexity in timelines and outcomes

Martin Price, Vice President, Health Economics, Market Access & Reimbursement, Janssen

    • Market Access
    • Patients
Accelerate patient access to new treatments – NICE Patient Pathways
  • Discuss pharma’s role in ensuring patient access and care are optimised for newly approved treatments
  • Explore NICE’s new initiative enhancing the clinical/patient guidance for treatment at the point of approval

Gillian Leng, Deputy Chief Executive Officer, NICE

Market Access Focused Roundtables

    • Market Access
    • Market Access
  • Patient + value = payer value: how to articulate new patient journey understanding into a language payers understand
  • Monopoly vs. Monopsony: risks and opportunities for companies and payers/health systems in joint value assessments and negotiations in Europe
  • Stronger value-based contracting: discuss key challenges and stumbling blocks in payer negotiations for value-based agreements
  • Italy’s outcomes-based experience: deep dive into the challenges and key learnings from the early movers into outcomes-based agreements in Europe
  • Master your ePRO/ePREM approach: discuss how to unlock more value-based access with greater patient outcome understanding
  • Market Access 101: learn the basics on the European Market Access landscape and internal pharma functionality
  • Internal access alignment: discuss how best to pool capabilities and define Market Access responsibilities
  • Globalisation vs regionalisation: understand how you can meet local market needs through different submission adaptation approaches

Agathe le Lay, Director, Head of HEOR , Lundbeck

Thomas Temme, Head of Value Demonstration & Access & Public Affairs Germany, Austria & Switzerland, Shire

Lara Pippo, Head of Italy Market Access , CSL

Redefine Medical’s Value

    • Medical Affairs
    • Medical Affairs
Panel: Medical as leader: discuss how a centralised medical function can improve dynamics with HCPs
  • See whether a concentrated medical HQ team can equip field teams with the skills and capabilities for more effective interactions
  • Discuss the strategic considerations in maintaining a balance of global and regional approaches

Christopher Keenan, Head, Worldwide Medical Customer Engagement, Medical Capabilities , BMS

José Antonio Burón Vidal, Vice President EMEA Medical Affairs, Johnson & Johnson

    • Medical Affairs
The evolution of Medical Affairs role in the Medicines Development Process
  • Make development patient-centric and value-oriented with a more strategic approach using Medical leadership
  • Understand the structural and capability requirements for involvement in the complete life cycle from idea generation on

Pol Vandenbroucke, SVP, Chief Development Officer, Pfizer Essential Health

    • Medical Affairs
Beyond education: become a source of inspiration for HCPs
  • Give HCPs revealing insights about patient populations and enable them to provide real service to patients

Mauricio Silva de Lima, VP, Medical Europe, Roche

Enhance Medical Interactions with Digital Excellence

    • Digital
    • Medical Affairs
    • Digital
    • Medical Affairs
Use digital as a driver for Medical authenticity and authority
  • Let Medical Affairs be Medical Affairs: Increase effectiveness and efficiencies using digital tools to enhance scientific exchange, medical education and medical programs
  • Explore emerging avenues of high quality data gathering with digital tools

Cesar Sanz Rodriquez, Associate Vice President, Medical Affairs Lead EURAM, MSD

    • Digital
    • Medical Affairs
The next-generation digital congress experience 
  • Amplify the value of your congress campaigns with innovative digital content and communications
  • Use relevant, real-time content to engage with your key customers and stakeholders to improve their congress experience

Felix Jackson, Founder and Medical Director, MedDigital

2019s Commercial Imperatives

    • Commercial
    • Medical Affairs
    • Digital
    • Commercial
    • Medical Affairs
Panel: The rep of tomorrow, today
  • Fast-track a new paradigm for your sales reps and MSLs
  • Define the balance of responsibilities and objectives throughout your whole field team

Dirk Abeel, Global Head - Medical Field Effectiveness, Nestle

Walter Sheloff, Customer Facing Medical Effectiveness Lead, Pfizer

Inge Bliestle, Director, Commercial Operations, Actelion

    • Commercial
    • Medical Affairs
Field Force Effectiveness Taskforce
  • Explore the evolution of pharma’s medical and commercial field force in a fast-changing external environment
  • In an hour-long interactive session hosted by field force leaders understand emerging capability requirements, measure effectiveness and ensure successful interactions

Heather Moses, Head of Medical Affairs, Roche

Walter Sheloff, Customer Facing Medical Effectiveness Lead, Pfizer

Dirk Abeel, Global Head - Medical Field Effectiveness, Nestle

Mauricio Silva de Lima, VP, Medical Europe, Roche

    • Commercial
    • Digital
Working towards 'better': How Google is making genuine helathcare breakthroughs
  • Successfully implement the change needed to constantly improve productivity and leverage data to make smarter decisions

Ryan Olohan, Managing Director, Healthcare, Google

    • Commercial
    • Digital
Being disruptive from within- The LEO Innovation Lab story
  • Hear how LEO Innovation Lab ensure agility and how they can continuously drive innovation
  • Find out how they use patient insights to leverage innovative new solutions in AI, assistant tools and machine learning.

John Zibert, Chief Medical Officer, LEO Innovation Lab

Be more than just a partner

    • Commercial
    • Digital
    • Digital
    • Commercial
An end-to-end view to your customer suite
  • Adopt a multi-customer model: Physicians, Payers, Policy Makers and Patients. Integrated multi-customer strategies are the way forward.

Ana Cespedes, Chief Operating Officer, IAVI

    • Digital
    • Commercial
Panel: The digitally mature sales function: how you can transform sales reps into catalysts
  • How real digital transformation will be dependent on capabilities of your customer-facing teams

Naji Gehchan, Chief Marketing Officer & Bio Medicines Leader - France, Eli Lilly

    • Commercial
Sandoz Case Study: Commercial Excellence: as strong as the weakest link
  • Understand the end-to-end process and understand that customer centricity as the key lighthouse and everything you need to do to ensure you meet the expected customer experience.

Gabriel Morelli, Global Head of Commercial Excellence, Sandoz International

    • Commercial
Customer Experience: how to design an intentional customer journey that resonates at every step
  • Plan the journey and action you want your customers to take and find the moments that you can move the needle

Luis Magarzo Bello, Commercial Excellence Head, Mylan

Genuine Patient Centricity through collaboration

    • Patients
    • Commercial
    • Market Access
    • Patients
Panel: From competitors to collaborators - form alliances in the interest of the patient
  • Stop creating your own platforms - co-create the one platform that patients admire

Carole Sian Scrafton, Patient Advocate,

    • Patients
    • Commercial
    • Market Access
Shape the business landscape
  • Learn how anticipation of policy changes and proactive engagement on advocacy and policy shaping can be a critical source of competitive advantage.

Lynn Taylor, SVP, Global Healthcare Government & Public Affairs, Merck Group

    • Commercial
    • Patients
How Takeda has implemented the patient comes first approach- and the benefits received
  • Ways your organisation can gain maximum patient insights for multiple applications without losing efficiency
  • Ways to deep understanding of patient perspectives and leveraging insights for multiple applications without losing focus

Gundula Schnidewind, Managing Director, Belgium, Takeda

    • Commercial
    • Patients
Establishing true patient outcomes, starting with the patient right from the R&D process
  • Focusing on patient outcomes when designing ‘pharma plus digital’ products
  • Building a patient focused cross-functional agile team to launch a product

Panos Papakonstantinou, Musculoskeletal Mobility Solutions Commercial Director, Novartis

Support Patients from start to finish

    • Patients
    • Patients
Start with the service to go beyond just 'beyond the pill'
  • Understand how true value can be translated from the patient rather than from the medicine or treatment regimen
  • Understand how Merck has implemented a cross functional patient culture through it’s pharma sector

Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

    • Commercial
    • Patients
Real advocacy - how to become your patient organisation's number one partner
  • Innovate at the cutting edge of patient communication to generate fans, not just advocates

David Montgomery, Vice President, Global Science Exchange, Pfizer Oncology

Redefine your business

    • Patients
    • Digital
    • Commercial
    • Digital
    • Commercial
Achieve personalization through Omni-channel, longitudinal & behavioral analysis.
  • Establish an Omni-channel customer view, understand customer decision journeys
  • Observe customer behaviors and gather insights over short campaign iterations

Philippe Kirby, Digital Capabilites and Marketing Lead, MSD

    • Digital
    • Patients
AbbVie case study: Crush Your FOMO – empowering a nation to take control of its health
  • Hear how AbbVie is collaborating with experts from outside the health industry in a bold preventative health move. By putting open-data at the forefront, AbbVie will explore the value of leveraging real-life, data-driven insights to further understand complex human behaviour, in order to ultimately help build a more sustainable NHS.

Gwenan White, UK Director of Communications and Patient Relations, Abbvie

    • Commercial
Dare to Dare: Redefine your customer approach and get ready for transformation
  • Change your perspective. Engage with patients as the key decision makers they’re becoming, and empower them to make educated decisions about their own health.
  • Go deep to understand the patient journey and core customer needs. Do it well, and the insights can reveal hidden value pools, and possibly force you to change your company strategy
  • Meet the needs of your customers by applying relevant digital tools. Implement by applying a start-up way of working, and it will be rocket fuel for your strategy.

Christina Molt Wengel, Senior Vice President and Head of Global Marketing , ALK Pharmaceuticals

    • Digital
    • Commercial
Panel: Streamlining of customer experience with an omnichannel approach
  • Envision how an industry leading company has created a truly integrated omni-channel offering
  • Equip different departments to begin the omni-channel transition and ensure the required capabilities are in place
  • Tailor your marketing strategy to ensure alignment between various platforms to ensure a seamless, consistent and effortless user experience

Florent Edouard, SVP, Global Head of Commercial Excellence and Customer Engagement, Grünenthal Group

Philippe Kirby, Digital Capabilites and Marketing Lead, MSD

Patient Experience for Patient Centricity

    • Patients
    • Commercial
    • Commercial
    • Patients
Convince skeptics and prove the commercial value of a patient-centric approach
  • Obtain senior-level support for patient initiatives by linking efforts to outcomes

Simon Eade, Head Global Commercial Strategy, Actelion

    • Commercial
    • Patients
You can’t stand still- innovate into new areas of helping patients
  • Learn how Takeda Austria is taking steps to innovate STEM cell therapy and deliver much needed medicines to patients
  • Understand the implications needed to work together to deliver this 48-hour treatment and how Takeda is over coming these barriers

Kirsten Detrick, Head, Central Europe and Austria, Takeda

Gain traction and harness technology

    • Digital
    • Commercial
    • Digital
LEO Pharma – Growth Hacking their way to the top
  • Hear how LEO Pharma is hacking their way into better HCP engagement, the results and challenges
  • Understand not only the challenges of building the function and the business case for digital marketing

Kasper Jerlang, Head of Global Digital Marketing and Engagement, LEO Pharma

    • Digital
    • Commercial
The digitally mature sales function: how you can transform sales reps into catalysts
  • How real digital transformation will be dependent on capabilities of your customer-facing teams

Naji Gehchan, Chief Marketing Officer & Bio Medicines Leader - France, Eli Lilly

    • Digital
    • Commercial
The bottom-up approach to driving commercial digital transformation as a global team
  • Driving business change based on local business cases rather than a one-size-fits-all – with results
  • Practical applications of AI and automation to drive local business value
  • Working with all levels – from General Managers to Marketers - to change the ways of working
  • The hidden roadblocks and time saps in a true digital transformation

Lanre Ibitoye, Director , Head of Digital Platforms and Capabilites- Europe & International Markets, Teva

Davidek Herron, Head of Outbound Digital Channels, Europe and Interantional Markets, Teva

The "Open your Eyes" stage

    • Data & RWE
    • The ‘Open your Eyes’ Stage
    • Medical Affairs
    • Market Access
    • Data & RWE
    • The ‘Open your Eyes’ Stage
Genomics and Blockchain: Decentralized genomic big data storage, sharing and analysis
  • Look into the future state of genomic data sharing and security as new technological advancements at the intersection of healthcare and information technology are developed.
  • Describe how blockchain technology can enable genomic data creation, ensure its security, and allow for its sharing
  • Discuss the future state of genomic research, genomic data security, genomic data standardization and data sharing between individuals and companies as whole genome sequencing costs continue to decrease.

Dennis Grishna, Co-Founder, Nebula Genomics

Kamal Obbad, Co-Founder, Nebula Genomics

    • Data & RWE
    • The ‘Open your Eyes’ Stage
The Digitome: The first digital representation of health and disease
  • Understand the Human Digitome Project: long-term vision for the platform, including opening it up so that anyone can proactively use it themselves, so that researchers will understand more about how diseases work, and how to cure them.
  • How AI is being used to look for patterns in the ways patients contract diseases and react to medication, to give doctors more information about people’s health
  • How blockchain enables patient-centric data

Michelle Longmire, CEO, Medable

    • The ‘Open your Eyes’ Stage
    • Medical Affairs
How single-cell transcriptomics will redefine human diseases and unearth novel therapeutic avenues
  • Everything you need to know about The Human Cell Atlas, an ambitious project, funded by the Chan-Zuckerberg Institute and others, to map every cell in the human body and how this could impact how drugs are developed
  • Learn how the single revolution is rewriting our understanding of a human disease ranging from cancer to inflammatory conditions

Sam Behjati, Wellcome Trust Intermediate Clinical Fellow, Wellcome Sanger Institute

    • The ‘Open your Eyes’ Stage
The first biopharma company to be born in the cloud
  • Understand how Moderna Therapeutics has evolved as a truly digital biopharma organization and what this means for advancing drug candidates to clinical studies; increasing the agility of its research, development, and manufacturing processes; and achieveing results—such as personalized cancer vaccines—that would have been impossible even a few years ago.
  • Lessons learnt from their journey and their vision for the future of the company and what this means for the future pharma business model

Marcello Damiani, CDO, Moderna Therapeutics

    • The ‘Open your Eyes’ Stage
Training our immune system to prevent and cure chronic diseases.
  • Understand that the prevention and management of chronic diseases should focus not only on symptomatic patients but on individuals that do not yet have symptoms.
  • Discuss how this disease-prevention strategy profoundly impacts clinical development, marketing and distribution of products, and new payor models.
  • Appreciate how digital strategies that affect an individual’s behaviour towards lifestyle choices, can enhance adherence to treatment and positively affect clinical outcome

Oliver Siegel, CEO, AFFiRiS

    • The ‘Open your Eyes’ Stage
Liberate the scientists! How AI is propelling a drug discovery revolution
  • Why the pharmaceutical industry is failing in the innovation imperative
  • Understand how AI can increase the efficiency and increase the chance of success of drug discovery and transform drug discovery as we know it
  • See how this disruption is already happening and show how AI can impact the whole value chain

Jackie Hunter, Chief Executive, Clinical Programmes & Strategic Relationships, Benevolent Bio

    • The ‘Open your Eyes’ Stage
PANEL: Without the pill: How digital therapeutics can drive market access innovation and herald in a new era of shared value
  • Discuss how the current partnership model is floored and why we need to be partnering for new kinds of value
  • Find out how the leading organizations are partnering by focusing on the friction and pain points of care, and building value alliances with key stakeholders

David Van Sickle, CEO, Propeller Health

Matthew Bonam, Head of Intelligent Pharmaceuticals, AstraZeneca

    • The ‘Open your Eyes’ Stage
    • Market Access
Reimburse digital solutions - lessons learnt from Germany’s most successful reimbursement case study
  • Understand how Sonormed successfully gained market access for Germany’s first health product mobile app before it’s even been developed
  • Explore the payer negotiation process and hear feedback from reimbursement considerations shaping product development

Jörg Land, CEO, Sonormed

Session SubHeading

    • Keynotes
  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator: Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

Ryan Olohan, Managing Director, Healthcare, Google

John Zibert, Chief Medical Officer, LEO Innovation Lab

Khair ElZarrad, Deptuy Director, Office of Medical Policy, FDA

  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator: Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

Ryan Olohan, Managing Director, Healthcare, Google

John Zibert, Chief Medical Officer, LEO Innovation Lab

Khair ElZarrad, Deptuy Director, Office of Medical Policy, FDA

I want to attend I want the Brochure